ライフサイエンスコーパス: pharmacokinetic

1 formulated drugs and play key roles in their pharmacokinetics.

2 oor bioavailability and undetectable in vivo pharmacokinetics.

3 ptor agonist fentanyl and characterized MCAM pharmacokinetics.

4 on resulting in dose-dependent and nonlinear pharmacokinetics.

5 esian estimates of plasma and intrapulmonary pharmacokinetics.

6 posure increased with dose, with time-linear pharmacokinetics.

7 -MRI), and computed correlates of crolibulin pharmacokinetics.

8 effects, low bioavailability, or undesirable pharmacokinetics.

9 in to enable multifactorial analysis of skin pharmacokinetics.

10 Secondary outcomes show no detriment to ATRA pharmacokinetics..

11 nts were randomized 1:1:1 to mavacamten at a pharmacokinetic-adjusted dose (targeting plasma levels o

12 We assessed MA and OA pharmacokinetics after ingestion of olive oils (OOs) wit

13 translation of the therapeutic, we present a Pharmacokinetic Algorithm Mapping GRI Efficacies in Rode

14 atment of multidrug-resistant organisms, and pharmacokinetic alterations that predispose to inadequat

15 e preclinical evaluation of LSPD in terms of pharmacokinetics, ammonia uptake, and toxicology to seek

16 Pharmacokinetic analyses included all participants who h

17 Pharmacokinetic analyses revealed that INT131 penetrates

18 Results of pharmacokinetic analysis and activity on [(18)F]fluorode

19 Intensive pharmacokinetic analysis of 13 patients for whom data we

20 undergoing an extended protocol for detailed pharmacokinetic analysis were included.

21 s blood samples and urine were collected for pharmacokinetic analysis.

22 dard nCRT was performed, as were exploratory pharmacokinetic and biomarker analyses.

23 -concept that polarized HLCs can be used for pharmacokinetic and drug-drug interaction studies.

24 ic-acid carriers because of their favourable pharmacokinetic and immunological properties and their a

25 ression-free survival, overall survival, and pharmacokinetic and pharmacodynamic analyses (primary re

26 apitulate organ-level (patho)physiology, yet pharmacokinetic and pharmacodynamic analyses require mul

27 make limited use of new understanding of the pharmacokinetic and pharmacodynamic contributors to effe

28 ex differences in immune function and opioid pharmacokinetic and pharmacodynamic parameters, structur

29 of 2 different elements, differences in the pharmacokinetic and pharmacodynamic profile of the agent

30 and tissues samples is required to study the pharmacokinetic and pharmacodynamic properties of antise

31 We determined the pharmacokinetic and pharmacodynamic properties of MVT-60

32 etermination of futuristic drug, SAL, during pharmacokinetic and pharmacodynamics studies.

33 in vitro activity, as well as more favorable pharmacokinetic and safety profiles than IP6 after subcu

34 We did pharmacokinetic and safety substudies within the open-la

35 gle-drug nanoparticles demonstrate excellent pharmacokinetic and toxicological profiles and dramatic

36 ally relevant TLR7 antagonist with favorable pharmacokinetics and 70.8% oral bioavailability in mice.

37 ns is complicated by the disparities in drug pharmacokinetics and activity.

38 ynergy with first-line drugs in macrophages, pharmacokinetics and adjunctive bactericidal activity, a

39 relationship was observed between pimodivir pharmacokinetics and age.

40 candidates were evaluated for their in vivo pharmacokinetics and biodistribution in rats.

41 ernalization, low cytotoxicity, controllable pharmacokinetics and biodistribution, have shown promisi

42 The pharmacokinetics and efficacy of these ADCs were further

43 avenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in p

44 Primary outcomes were safety, pharmacokinetics and imaging feasilibity of ONM-100.

45 Plasma islatravir pharmacokinetics and intracellular islatravir-triphospha

46 cilitates better understanding of (18)F-FGln pharmacokinetics and may be necessary for response asses

47 To determine the pharmacokinetics and pharmacodynamics (PKPD) of ciproflo

48 values at time of IFE were estimated through pharmacokinetics and pharmacodynamics simulation, IFE ou

49 2/CD25 fusion protein, with greatly improved pharmacokinetics and pharmacodynamics when compared with

50 mework combines viral dynamics with antibody pharmacokinetics and pharmacodynamics, and will be gener

51 culosis, the nanoparticles provided improved pharmacokinetics and pharmacodynamics.

52 ver study was used to assess plasma nicotine pharmacokinetics and product liking for two e-cigarettes

53 pertzian tumor growth with antibody-mediated pharmacokinetics and radiation-induced cell killing.

54 discovered as a 5-HT(2C)R PAM with improved pharmacokinetics and reduced off-target interactions rel

55 xtrapolation for better predictions of human pharmacokinetics and risk of DDIs.

56 We aimed to assess the terminal phase pharmacokinetics and safety of long-acting injectable ca

57 iver and therefore a determinant of clinical pharmacokinetics and site of drug-drug interactions.

58 Together with promising pharmacokinetics and toxicology profiles, these results

59 e dependence treatment may alter the cocaine pharmacokinetics and/or attenuate cocaine-induced reward

60 onoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children an

61 In part 2, we have evaluated the safety, pharmacokinetics, and antiviral activity of multiple dos

62 kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravt

63 of our knowledge, this is the first time MA pharmacokinetics, and effects on endothelial function in

64 Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by

65 dly impacts on their in vivo immunogenicity, pharmacokinetics, and functional attributes.

66 9 were well tolerated, showed dose-dependent pharmacokinetics, and had potent antiviral activity in p

67 nfluence recognition of the intended target, pharmacokinetics, and off-target effects.

68 tudy investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in h

69 The safety, pharmacokinetics, and pharmacodynamics of MMV390048 supp

70 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses

71 surgery can influence absorption, excretion, pharmacokinetics, and pharmacodynamics of various antico

72 ss safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics.

73 to determine safety, tracer biodistribution, pharmacokinetics, and radiation dosimetry.

74 provements in efficacy, metabolic stability, pharmacokinetics, and safety profiles.

75 ithout HIV, we aimed to characterise safety, pharmacokinetics, and virological suppression in adults

76 armacokinetics was explored via a population pharmacokinetic approach in 40 volunteers who received o

77 assessed by incidence of adverse events) and pharmacokinetics (assessed by serum atezolizumab concent

78 ade 3 or higher) and dolutegravir population pharmacokinetics, assessed in participants who began rif

79 vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a

80 Pharmacokinetic assessment of AFM13 in the combination s

81 nts who adhered to prespecified criteria for pharmacokinetic assessment).

82 The pharmacokinetics associated with these 4 chelator-linker

83 ghts the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically ac

84 surface modifications, formulations aspects, pharmacokinetic behavior and efficacy towards the treatm

85 es in cycles 1 and 2 and provided a pre-dose pharmacokinetics blood sample on day 1 of cycle 3.

86 r release kinetics have been able to improve pharmacokinetics but are not ideal for drugs with short

87 Misspecification of pharmacokinetics can lead to wrongly predicted timing or

88 There are many pharmacokinetic challenges associated with administering

89 Pharmacokinetic concentration, biotransformation, and DA

90 tive assays, an enhanced appreciation of the pharmacokinetic consequences of immunogenicity and the d

91 We fitted a standard EMB pharmacokinetic curve to determine the time when fish tr

92 resistant cells where drug interactions and pharmacokinetic curves can be estimated from user-provid

93 ns (C(trough)) were based on reference adult pharmacokinetic data and safety was evaluated in all chi

94 Pharmacokinetic data from plasma and cerebrospinal fluid

95 ve approach is to take advantage of existing pharmacokinetic data from these smaller cohorts to enabl

96 Finally, first pharmacokinetic data of these natural products are discl

97 their formulations and consequent effect on pharmacokinetic distribution of delivered active compone

98 ophilicity on individual parameter values in pharmacokinetic equations.

99 The pharmacokinetic-evaluable population included all patien

100 lysis of SAL in biological fluids and during pharmacokinetic evaluation in rabbit plasma.

101 ible binding to mu opioid receptors) and not pharmacokinetic factors play a significant role in its l

102 (203)Pb-L1-(203)Pb-L5 demonstrated favorable pharmacokinetics for (212)Pb-based TRT.

103 models) were used to perform simulations of pharmacokinetics for different combinations of perfusion

104 selective CSF1R inhibitor, showed favorable pharmacokinetics for inhalational treatment and intranas

105 Safety, pharmacokinetics, forced expiratory volume in 1 second,

106 Pharmacokinetics-guided lead optimization resulted in th

107 ncorporated VRC01 neutralization using serum pharmacokinetics (HVTN 104) and in vitro pharmacodynamic

108 less than 25 kg, we assessed dolutegravir's pharmacokinetics in children given once daily 25 mg film

109 e primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65-85 years) versus no

110 tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of it

111 We investigated dolutegravir population pharmacokinetics in maternal plasma, cord, breastmilk an

112 nsing technologies, capable of tracking drug pharmacokinetics in noninvasively retrievable biofluids

113 ives: To characterize rifapentine population pharmacokinetics, including autoinduction, and determine

114 e gaps, test potential solutions using human pharmacokinetics informed through preclinical infection

115 nd-generation drugs are less likely to cause pharmacokinetic interactions than their older counterpar

116 derstanding of renal physiology and diuretic pharmacokinetics is essential for skillful use of diuret

117 measure antibody biodistribution and tissue pharmacokinetics is well established, but current PET sy

118 ts with grade 2 or worse adverse events, and pharmacokinetics, measured by apparent terminal phase ha

119 Adverse events and pharmacokinetic measurements were assessed.

120 Using direct pharmacokinetic measurements, we show that 25(OH)D clear

121 d primary outcome components, biological and pharmacokinetic measures, and adverse events graded 2 or

122 conducted a systematic investigation of THC pharmacokinetics, metabolism and distribution in blood a

123 A population pharmacokinetic model to assess nevirapine exposure was

124 A physiologically based pharmacokinetic model, fit to and validated using these

125 ulated using previously published population pharmacokinetics model at dose 10-40 mg/kg for weight-ba

126 Pharmacokinetic modeling of hydroxychloroquine suggested

127 To assist with accurate pharmacokinetic modeling of the training cohort, a metho

128 Pharmacokinetic modeling predicts that most high dose re

129 Pharmacokinetic modeling with both reversible and irreve

130 netic samples were assessed using population pharmacokinetics modeling.

131 Population pharmacokinetic modelling generated estimates of drug ex

132 Perfusion properties can be estimated from pharmacokinetic models applied to DCE-MRI data using cur

133 Population pharmacokinetic models were fit to estimate steady-state

134 Pharmacokinetic monitoring is insufficient to estimate t

135 virus-specific T cell levels in addition to pharmacokinetic monitoring seems safe, results in a simi

136 In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin

137 The pharmacokinetics of a deuterated compound depends on the

138 in vitro models that match the physiological pharmacokinetics of drug exposure.

139 is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs.

140 To date, pharmacokinetics of maslinic (MA) and oleanolic (OA) aci

141 cted to assess the safety, tolerability, and pharmacokinetics of MP0250 in 45 patients with advanced

142 The pharmacokinetics of nanoparticle-borne drugs targeting t

143 y investigated the safety, tolerability, and pharmacokinetics of nilotinib, and measured biomarkers i

144 pulse model that closely mimics the in vivo pharmacokinetics of platinum therapy, we profiled cispla

145 Effects of different genotypes on the pharmacokinetics of probe substrates may support their u

146 ed to describe the plasma and intrapulmonary pharmacokinetics of rifampicin, isoniazid, pyrazinamide,

147 Data are lacking on the safety and pharmacokinetics of single-dose BIVV001.

148 great potential for real-time monitoring of pharmacokinetics of small molecules associated with live

149 The pharmacokinetics of these BiNPs can be easily improved v

150 The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo i

151 We investigate the pharmacokinetics of this conjugate in mice and show that

152 flux pumps that are strongly involved in the pharmacokinetics of various drugs and nutrient distribut

153 ulness of the preclinical models in enabling pharmacokinetic optimization for acid/zwitterionic drug

154 Finally, we report a pharmacokinetic-optimized, metabolically stable derivati

155 potential effects of cebranopadol on cocaine pharmacokinetics or cocaine-induced hyperactivity.

156 Pharmacokinetic outcomes were estimated using non-compar

157 Hepatic metabolic stability is a key pharmacokinetic parameter in drug discovery.

158 an in vitro inhibitory assay to evaluate its pharmacokinetic parameters and potency in a CDI mouse mo

159 ncy against the GRK2 subfamily and favorable pharmacokinetic parameters in mice.

160 Pimodivir pharmacokinetic parameters in non-elderly and elderly pa

161 Using pharmacokinetic parameters of TLZ in humans, we designed

162 itochondrial membrane potential with the key pharmacokinetic parameters of TPP inside the live cells.

163 of ex vivo nude mouse ear skin and extracted pharmacokinetic parameters through convolutional neural

164 healthy humans for safety, tolerability, and pharmacokinetics paved the way for its further developme

165 We built a physiologically based pharmacokinetic (PBK) model to simulate concentrations o

166 DOTATATE therapy using physiologically based pharmacokinetic (PBPK) modeling considering, first, a de

167 The pharmacokinetic performance of the delivered insulin ind

168 itative in nature, but can be coupled with a pharmacokinetic/pharamacodynamic (PKPD) model providing

169 Pharmacokinetic-pharmacodynamic activity of compound 42

170 Pharmacokinetic-pharmacodynamic curves showed a linear r

171 On the basis of safety and pharmacokinetic-pharmacodynamic data, the avadomide RP2D

172 Current pharmacokinetic-pharmacodynamic models mainly focus on t

173 -to-event analysis on the treated set]), and pharmacokinetic-pharmacodynamic relationships (descripti

174 d of care in terms of efficacy, with similar pharmacokinetic-pharmacodynamic relationships as those s

175 ishment of in vitro-in vivo correlations and pharmacokinetic-pharmacodynamic relationships to optimiz

176 hese factors on the probability of attaining pharmacokinetic-pharmacodynamic target goals is essentia

177 Pharmacokinetic/pharmacodynamic relationships of dabigat

178 Finally, a pharmacokinetic/pharmacodynamic study was conducted in c

179 ief but intensive course of eculizumab using pharmacokinetic/pharmacodynamic-guided dosing, requiring

180 We report the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary effi

181 Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinic

182 rent modeling strategies, such as population pharmacokinetics/pharmacodynamics (PK/PD) and systems bi

183 clinical evaluation, including a comparative pharmacokinetics/pharmacodynamics study that is usually

184 a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics.

185 s based on bioreceptor.drug antagonism or by pharmacokinetic (PK) approaches that seek to reduce the

186 Immunoaffinity (IA) LC-MS/MS pharmacokinetic (PK) assays are widely used in the field

187 st human dose of a novel candidate drug, the pharmacokinetic (PK) behavior of the drug in humans is p

188 fore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behaviora

189 enhance cGAMP delivery - we investigate the pharmacokinetic (PK)-pharmacodynamic (PD) relationships

190 sive bioanalytical characterization of their pharmacokinetics (PK) and catabolism in both preclinical

191 , the lack of reliable data on antimicrobial pharmacokinetics (PK) at infection sites hinders efforts

192 Here, plasma pharmacokinetics (PK) data of the OPTILIV trial in which

193 of this study was to characterize the plasma pharmacokinetics (PK) of cannabinoids and their metaboli

194 The pharmacokinetics (PK) of endothelial surface-targeted af

195 Compound 6f also demonstrated excellent pharmacokinetics (PK) profile (high oral bioavailability

196 es 13, 29, 32, 43, and 51 showed a favorable pharmacokinetics (PK) profile across different species a

197 her coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing

198 This pharmacokinetics (PK) study assessed DMPA among HIV/TB c

199 munoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the

200 Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) perfor

201 of multitarget drugs is advantageous from a pharmacokinetic point of view.

202 tuzumab plus trastuzumab in the per-protocol pharmacokinetic population (all enrolled patients who ad

203 bioactive compounds, positively influencing pharmacokinetics, potency and conformation.

204 Improvements in in vitro ADME tools and pharmacokinetic prediction models have helped to shift a

205 mpound 28 showed good in vitro potency, with pharmacokinetic profile across species with excellent br

206 on of compound 42 with excellent potency and pharmacokinetic profile are discussed.

207 CSL040 also showed an improved pharmacokinetic profile compared with the full extracell

208 bility in all species, linked to an adequate pharmacokinetic profile in rodents, and antinociceptive

209 We characterized the pharmacokinetic profile of apixaban by assessing differe

210 c to reduce the side effects and improve the pharmacokinetic profile of chemotherapeutic drugs.

211 roperties, further reflected in the enhanced pharmacokinetic profile of the most advanced compounds,

212 generally difficult to determine the in vivo pharmacokinetic profile of these compounds.

213 show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-a

214 Also, we show that Sor has a better pharmacokinetic profile than Rif, making it a suitable s

215 Molecules were designed to have ultra-long pharmacokinetic profile to minimize variability in plasm

216 exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary ant

217 ty across species, and exhibited a favorable pharmacokinetic profile.

218 mbination treatment strategies with flexible pharmacokinetic profiles and multidrug interaction curve

219 mbination treatment strategies with flexible pharmacokinetic profiles and multidrug interaction curve

220 ounds possess promising in vitro and in vivo pharmacokinetic profiles and show potent on target inhib

221 tablets given once daily provide appropriate pharmacokinetic profiles in children weighing 20 kg or m

222 Consistent pharmacokinetic profiles, high target specificity, and r

223 release kinetics leading to their respective pharmacokinetic profiles.

224 st ALK2, excellent selectivity, and superior pharmacokinetic profiles.

225 iculties including adverse toxicity and poor pharmacokinetic profiles.

226 turn, will also improve drug solubility and pharmacokinetic profiles.

227 in inflammation, as well as characterize its pharmacokinetic properties and brain penetration.

228 infection imaging agents encompassing better pharmacokinetic properties and in vivo stability than ot

229 Its deduced pharmacokinetic properties appear suitable for further d

230 coupled from endogenous VWF and has enhanced pharmacokinetic properties compared with all previous FV

231 challenges related to weak potency and poor pharmacokinetic properties have hampered their developme

232 The aim of this study was to investigate its pharmacokinetic properties in patients with cancer.

233 efficacy, excellent target selectivity, and pharmacokinetic properties including good brain permeabi

234 eplacements to improve the potency (IC(50)), pharmacokinetic properties including the free fraction (

235 wever, when optimizing the target-binding or pharmacokinetic properties of cyclic peptides, it is fre

236 Pharmacokinetic properties were assessed in mice for com

237 molecular properties, drug likeness through pharmacokinetic properties, and associated network with

238 am focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new sel

239 to I-BET469, which possesses favorable oral pharmacokinetic properties, displays activity in vivo, a

240 crease potency, enhance selectivity, improve pharmacokinetic properties, eliminate toxicity, and acqu

241 probability of favorable drug metabolism and pharmacokinetic properties, including good oral bioavail

242 ssive in vivo efficacy and overall promising pharmacokinetic properties, indicating their therapeutic

243 rin inhibitors for their physicochemical and pharmacokinetic properties, resulting in the identificat

244 s as well as poor solubility, stability, and pharmacokinetic properties.

245 gher activity against nSMase2 with favorable pharmacokinetic properties.

246 vital to determine production efficiency or pharmacokinetic properties.

247 ike molecules with favorable bioactivity and pharmacokinetic properties.

248 nolics were evaluated by their molecular and pharmacokinetics properties and disease association netw

249 ysicochemical as well as drug metabolism and pharmacokinetics properties and finally in vivo proof-of

250 Compound 48c showed good pharmacokinetics properties in mice via intraperitoneal

251 for administration, and poor selectivity and pharmacokinetics resulting in off-target toxicity and in

252 ide) of quercetin found in human plasma, the pharmacokinetics results have demonstrated an increased

253 ug interactions (DDIs) leading to changes in pharmacokinetics, safety and efficacy.

254 We demonstrate favourable pharmacokinetics, safety, tolerability, dose-dependent P

255 Sparse pharmacokinetic samples were assessed using population p

256 Dolutegravir pharmacokinetic sampling (0-24 hours) was undertaken 14

257 he same schedule and had sparse dolutegravir pharmacokinetic sampling at weeks 8, 11, and 16.

258 Intensive pharmacokinetic sampling conducted in each age group con

259 Pharmacokinetic simulations showed that current weight-b

260 ity and the potential to greatly improve the pharmacokinetics, stability, and downstream developabili

261 We obtained descriptive safety and pharmacokinetics statistics, and estimated efficacy resu

262 corresponding weight bands who consented to pharmacokinetic studies and received the studied doses.

263 Pharmacokinetic studies are therefore needed to define t

264 However, pharmacokinetic studies are time-consuming, resource int

265 To monitor silver concentrations, pharmacokinetic studies can be performed.

266 e, synergism, P-glycoprotein inhibition, and pharmacokinetic studies in in vitro and in vivo human an

267 Pharmacokinetic studies in mice confirmed that FD&C Red

268 Pharmacokinetic studies in mice demonstrated that the le

269 Pharmacokinetic studies in mice, rats and dogs revealed

270 Pharmacokinetic studies of released drugs after intraven

271 on to their efficacy, we undertook the first pharmacokinetic studies on these prodrugs.

272 Pharmacokinetic studies revealed rapid absorption of Rh-

273 In vivo pharmacokinetic studies showed that miR-18a reaches the

274 tuberculosis infection.Methods: Rifapentine pharmacokinetic studies were identified though a systema

275 Mouse pharmacokinetic studies with oral administration of 23dd

276 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regardin

277 e, both compounds were bioavailable in mouse pharmacokinetic studies, and compound 6 is the first EGF

278 scopy, mass spectrometry and mechanistic and pharmacokinetic studies, there has been considerable int

279 We conducted a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (

280 ntibody formats from both in vitro serum and pharmacokinetic study samples.

281 In a dedicated pharmacokinetic study to compare GFR with tubular secret

282 A Phase 1 safety and pharmacokinetic study was conducted: a single subcutaneo

283 Pharmacokinetics study demonstrated adipoRon (APN recept

284 95% CI, 0.34-0.65) and a 2.6 greater odds of pharmacokinetic target attainment (odds ratio, 2.63; 95%

285 kidney injury and a 2.6-fold higher odds of pharmacokinetic target attainment when compared with int

286 Secondary outcomes included mortality and pharmacokinetic target attainment.

287 In vivo pharmacokinetic testing of 90 in rats revealed that the

288 osslinked Rososome with better stability and pharmacokinetics than its non-crosslinked counterpart.

289 matologists with less consideration of their pharmacokinetics than that of conventional synthetic DMA

290 based excipients to yield a formulation with pharmacokinetics that is faster than the currently avail

291 meter V(p) was calculated by using the Tofts pharmacokinetic two-compartment model.

292 , at the same time being associated with low pharmacokinetic variability and good tolerability.

293 tyltransferase 2 (NAT2) gene explain >88% of pharmacokinetic variability.

294 Research Site, Tembisa, South Africa), with pharmacokinetic visits done at VxPharma (Pretoria, South

295 ionship between SNP combinations and digoxin pharmacokinetics was explored via a population pharmacok

296 cs and intracellular islatravir-triphosphate pharmacokinetics were approximately dose proportional.

297 tion, as well as improvements in potency and pharmacokinetics were desirable for discovering pipeline

298 Pharmacokinetics were dose proportional and exceeded pre

299 Pharmacokinetics were highly variable among subjects and

300 ss than 40 kg, we also assessed dolutegravir pharmacokinetics within-subject on film-coated tablet do